HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Squamous Cell Neoplasms (Squamous Cell Cancer)

Subscribe to New Research on Squamous Cell Neoplasms

Neoplasms composed of squamous cells of the epithelium. The concept does not refer to neoplasms located in tissue composed of squamous elements.

Also Known As:

Squamous Cell Cancer; Neoplasms, Squamous Cell; Cancer, Squamous Cell; Cancers, Squamous Cell; Cell Cancer, Squamous; Cell Cancers, Squamous; Cell Neoplasm, Squamous; Cell Neoplasms, Squamous; Neoplasm, Squamous Cell; Squamous Cell Cancers; Squamous Cell Neoplasm

Networked: 1188 relevant articles (58 outcomes, 226 trials/studies)

Relationship Network

Disease Context: Research Results

Neoplasms: 649836
- Neoplasms by Histologic Type: 1
  - Glandular and Epithelial Neoplasms: 332
    - Squamous Cell Neoplasms: 1188

Related Diseases

1.	Neoplasms (Cancer)
2.	Neoplasm Metastasis (Metastasis)
3.	Adenocarcinoma
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
5.	Carcinoma (Carcinomatosis)

Experts

1.	Forastiere, Arlene A: 8 articles (06/2014 - 10/2002)
2.	Psyrri, Amanda: 8 articles (06/2014 - 02/2005)
3.	Fury, Matthew G: 7 articles (06/2014 - 02/2011)
4.	Krecicki, Tomasz: 6 articles (02/2016 - 09/2004)
5.	Harrington, Kevin J: 6 articles (11/2014 - 02/2009)
6.	Nutting, Christopher M: 6 articles (11/2014 - 02/2009)
7.	Bhide, Shreerang A: 6 articles (11/2014 - 02/2009)
8.	Pfister, David G: 6 articles (06/2014 - 06/2011)
9.	Sasaki, Clarence: 6 articles (04/2010 - 02/2005)
10.	Lange, Dariusz: 5 articles (10/2015 - 01/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Squamous Cell Neoplasms:

1.	Cisplatin (Platino)FDA LinkGeneric 01/01/1988 - "Simultaneous therapy with high-dose cisplatin and radiation for unresectable squamous cell cancer of the head and neck: a phase I-II study." 07/01/1984 - "Cisplatin plus dichloromethotrexate is an active drug combination in squamous cell cancer of the head and neck, and deserves further evaluation in randomized studies and in an adjuvant setting." 07/01/1984 - "A phase I-II trial of cisplatin and dichloromethotrexate in squamous cell cancer of the head and neck." 07/15/2002 - "Cisplatin has been the most promising single chemotherapeutic agent usedagainst head and neck squamous cell cancer to date. " 03/01/1997 - "Cisplatin is an effective anti-neoplastic agent used in the treatment of squamous cell cancer of the head and neck, but with serious side effects. "
2.	Fluorouracil (Carac)FDA LinkGeneric 11/01/1999 - "An orthotopic model of squamous cell cancer of the head and neck was used in vivo to study the CD/5-FC system both alone and with concurrent radiation due to the radiosensitizing properties that 5-FU generates in situ. " 02/01/1991 - "A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck." 01/01/2012 - "Low-dose continuous infusional PTX over 16-hours and 5-fu over 24-hours is a promising regimen with good tolerability in treating patients with advanced esophageal squamous cell cancer." 12/01/1992 - "Twenty-two patients with inoperable Stage III and IV squamous cell cancer were treated with CDDP (30 or 35 mg/m2 for 5 days every 4 weeks for three courses) and 5-FU (200 or 300 mg/m2 per day continuous i.v. infusion for 12 weeks) with concomitant conventional radiation therapy. " 01/01/1992 - "Intra-arterial versus intravenous 5-fluorouracil infusion was compared in a naturally occurring, auricular epidermal squamous cell cancer in sheep. "
3.	cetuximab (Erbitux)FDA Link 11/01/2012 - "A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer." 01/01/2012 - "This current study evaluated eight cases of locally advanced and refractory basal cell or squamous cell cancers which were treated with cetuximab. " 01/01/2015 - "The 2 year progression-free survival and overall survival were similar between cetuximab group and no cetuximab group in patients with locally advanced head and neck squamous cell cancer. " 01/01/2014 - "Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series." 03/01/2013 - "Cetuximab was the first novel agent to obtain regulatory approval in the United States for the treatment of patients with Head and Neck Squamous Cell Cancer HNSCC. "
4.	irinotecan (Camptosar)FDA LinkGeneric 07/01/2003 - "CPT-11 as single-agent therapy is modestly effective against squamous cell cancer of the esophagus." 05/01/2004 - "The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11." 12/01/2001 - "CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein." 12/01/2001 - "In this study, we aim to evaluate the effects of CPT-11 on esophageal squamous cell cancers (ESCC) and to determine the correlation between the effects and the levels of Topo I expression. " 05/01/2003 - "These findings suggest that the combination chemotherapy with CPT-11 and nedaplatin for squamous cell cancer of uterine cervix is very useful in clinical practice. "
5.	Paclitaxel (Taxol)FDA LinkGeneric 04/01/1999 - "Because of its inherent activity against squamous cell cancer of the head and neck and its radiation-sensitizing properties, paclitaxel may be a valuable agent in the treatment of this patient population. " 08/01/1997 - "An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix." 04/01/2015 - "Paclitaxel (PTX) is broadly considered the drug of choice for treating human esophageal squamous cell cancer (ESCC). " 12/01/2011 - "Paclitaxel, a microtubule-stabilizing chemotherapeutic agent, has established clinical activity in squamous cell cancer of the head and neck. " 04/01/2007 - "Both moderately and poorly differentiated squamous cell cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 52.01%, 49.21%, and 40.02% for the former, and 60.02%, 61.16%, and 48.75% for the latter. "
6.	DNA (Deoxyribonucleic Acid)IBA 12/01/2015 - "The presence of human papillomavirus (HPV) DNA in oropharyngeal squamous cell cancer (OPSCC) tissue appears to be a strong predictor of improved prognosis, but this observation has not been explored in a population-based sample with generalisable findings. " 03/01/2013 - "This study enrolled 73 Japanese patients classified with Stage IIA-IV thoracic esophageal squamous cell cancer, and also investigated their CRP genetic polymorphisms using DNA extracted from their peripheral blood. " 11/01/2004 - "While evaluating the validity of using normal human mucosal cells from the upper aerodigestive tract as diploid standards for DNA content studies of squamous cell cancer of head and neck by flow cytometry, pseudoaneuploidy was frequently detected. " 11/01/2000 - "The purpose of the study was to evaluate the frequency of abnormal DNA content in squamous cell cancer (SCC) and analyze its correlation with late survival rates after surgical treatment. " 10/01/2015 - "Human papillomavirus DNA in pharyngeal scrapes as a marker of HPV-related squamous cell cancer of the oropharynx."
7.	Epidermal Growth Factor Receptor (EGF Receptor)IBA 12/01/2015 - ": The epidermal growth factor receptor (EGFR) is overexpressed in more than 80% of squamous cell cancers of the head and neck (SCCHN). " 05/01/2015 - "Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung." 07/01/2010 - "Epidermal growth factor receptor (EGFR) is overexpressed in several epithelial malignancies, including head and neck squamous cell cancer. " 05/01/2009 - "[Relation between epidermal growth factor receptor (EGFR) and p53 expression and radiocurability of laryngeal squamous cell cancer]." 01/01/2009 - "Exons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neck."
8.	Methotrexate (Mexate)FDA LinkGeneric 11/01/1987 - "Three hundred and thirteen patients with squamous cell cancer of the head and neck were entered in a randomised clinical trial to determine whether the addition of methotrexate during the course of irradiation improved the rate of primary control and subsequent survival. " 07/01/1995 - "To compared the response rates and the toxicity of the new antifolate edatrexate (EDX) with that of methotrexate (MTX) in a randomized trial in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCC) and to compare the durations of response and survival. " 01/01/1981 - "Fifty-eight patients with advanced squamous cell cancer of the head and neck have been randomized on a study comparing three different weekly methotrexate (MTX) dose levels followed at 24 hours by standardized folinic acid rescue. " 02/01/1978 - "Thirteen patients with metastatic squamous cell cancer of the lung were treated, in a nonrandomized study, with an oral high-dose methotrexate and citrovorum factor rescue regimen. " 01/01/1994 - "Between March 1990 and March 1992, 89 patients with recurrent and/or metastatic squamous cell cancer of the head and neck were randomised to receive either intravenous methotrexate (MTX) at a weekly dose of 40 mg/m2 plus lonidamine (LND) given orally at a starting dose of 75 mg three times daily for 3 days and then at a dose of 150 mg three times daily (arm MTX + LND) or methotrexate alone (arm MTX) at the same doses as arm MTX + LND. "
9.	Biological Markers (Surrogate Marker)IBA 01/01/2015 - "Expression of KRT13, FAIM2 and CYP2W1 appears to be influenced by risk habits, thus exploring the associations of these genes in oral squamous cell cancer (OSCC) with risk habits, clinico-pathological parameters and patient survival may be beneficial in identifying relevant biomarkers with different oncogenic pathways. " 01/01/2008 - "A long-term goal of our group is to develop proteomic-based approaches to the detection and use of protein biomarkers for improvement in diagnosis, prognosis, and tailoring of treatment for head and neck squamous cell cancer (HNSCC). " 01/01/2014 - "Serum biomarkers may be useful in the evaluation of suspected head and neck squamous cell cancer (HNSCC) and as indicators of treatment success or failure in adjuvant and chemopreventive clinical trials. " 06/30/2015 - "The prediction of therapy response in head and neck squamous cell cancer (HNSCC) requires biomarkers, which are also a prerequisite for personalised therapy concepts. " 03/01/2014 - "Clinical significance of head and neck squamous cell cancer biomarkers."
10.	pemetrexed (MTA)FDA Link 02/15/2011 - "A phase 1 study of pemetrexed plus gemcitabine given every 2 weeks demonstrated encouraging preliminary efficacy against head and neck squamous cell cancer (HNSCC). " 02/15/2011 - "A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer." 06/01/2012 - "Pemetrexed, a folate metabolic antagonist, is considered to be effective against plural mesotheliomas, non-small cell lung cancer, and especially for non-squamous cell cancer. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 08/01/1979 - "Complete remission of a squamous cell cancer of the mandible by chemotherapy. " 12/01/1978 - "Until chemotherapy is proved more effective in the initial management of squamous cell cancer of the mouth and throat, radiation and surgery will remain the principal treatment modalities. " 05/01/2006 - "Because of the low efficacy of the present chemotherapy regimens, one should follow new strategies, comparable to those initiated for squamous cell cancer of other organs." 11/01/1985 - "Recent studies have shown improved efficacy of chemotherapy in patients with advanced squamous-cell cancer of the head and neck. " 01/06/2015 - "A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes."
2.	Radiotherapy 11/01/2011 - "Altered fractionated radiotherapy (RT) has been shown to improve locoregional control (LRC) and overall survival (OS) in squamous cell cancer of the head and neck (SCCHN). " 06/01/2015 - "The purpose of this study was to report the long-term outcome of patients with squamous cell cancer (SCC) of the tonsil managed by surgery followed by postoperative radiotherapy (PORT). " 08/01/2014 - "This study aimed to analyze the differences in quality of life (QOL) in head and neck stage IV squamous cell cancer patients treated with surgery and reconstruction versus radical radiotherapy.The" 01/01/2012 - "In this study we analyzed the influence of PTEN expression on the outcome of a randomized clinical trial of conventional versus 7-days-a-week postoperative radiotherapy for squamous cell cancer of the head and neck. " 07/01/2010 - "The study involved 26 patients with squamous cell cancers of the head and neck region who received radiotherapy to a dose of 30 Gy in 10 fractions over a 2-week period as part of a split-course technique. "
3.	Neck Dissection (Radical Neck Dissection) 11/01/2014 - "Neck dissection in relation with disease-free, disease-specific, and overall survival of patients with squamous cell cancer of the oral cavity." 01/01/2007 - "Improved knowledge about the metastatic behavior of mucosal squamous cell cancer of the head and neck made it possible to reduce the extension of elective and even therapeutic neck dissections by sparing selected levels, thereby reducing morbidity. " 03/01/2012 - "This study examined the feasibility and safety of transaxillary and retroauricular ("TARA") approach for robotic neck dissection in patients with head and neck squamous cell cancer. " 07/01/2008 - "The study included 81 patients treated by surgery including neck dissection for oral or oropharyngeal squamous cell cancer. " 11/01/1998 - "This study is primarily based on an analysis of patients from January 1, 1989, through June 4, 1996 assigned to a protocol evaluating resection of oral cavity squamous cell cancer with margin control using Mohs' histographic technique and/or a group of patients with neck assessment of NO on clinical examination who are undergoing supraomohyoid neck dissections. "
4.	Esophagectomy 11/01/2005 - "Esophagectomy thus has become a safe operation and remains the only therapeutic option offering cure for a substantial proportion of patients with squamous cell cancer of the esophagus." 07/01/2011 - "The study participants were 159 Japanese patients treated for thoracic esophageal squamous cell cancer with curative esophagectomy at Akita University Hospital. " 08/01/2015 - "This technique was evaluated in 39 consecutive cases of prone esophagectomy for squamous cell cancer. " 04/01/2012 - "Between 1996 and 2010, 10 patients were diagnosed in our hospital with esophageal squamous cell cancer in the residual cervical esophagus after undergoing thoracic esophagectomy and were treated with endoscopic or surgical resection. " 01/01/2012 - "50 patients with loco-recurrent squamous-cell cancer after curative esophagectomy were retrospectively analyzed. "
5.	Combination Drug Therapy (Combination Chemotherapy) 09/01/2007 - "Debulking for stage IIIc ovarian squamous cell cancer was performed and she received adjuvant combination chemotherapy. " 09/15/1983 - "In 16 patients with recurrences of squamous cell cancer of the upper aerodigestive system a combination-chemotherapy was performed in three cycles. " 07/01/1989 - "Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer." 09/01/1984 - "Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck." 02/15/1986 - "The degree of differentiation of previously untreated squamous cell cancers of the head and neck does not conclusively predict tumor response to combination chemotherapy, but may reflect differences in natural history. "